Biotech

All Articles

FDA locations Kezar lupus test in grip complying with 4 individual deaths

.The FDA has placed Kezar Lifestyle Sciences' lupus trial on hold after the biotech flagged 4 fatali...

Phase 3 Scholar Rock trial hits SMA objective, sending out stock up 200%

.A phase 3 trial of Scholar Rock's back muscular atrophy (SMA) applicant has hit its key endpoint, s...

CAMP 4 is actually most recent to eye IPO, while Upstream define $182M strategy

.RNA biotech CAMP4 Therapeutics has actually marked out plans for a $67 million IPO, with inflammati...

Galecto purchases leukemia drug, falls bone tissue cancer resource in pivot

.A year after the breakdown of an idiopathic pulmonary fibrosis candidate sent Galecto on a search f...

Judo throws down $100M to knock senseless kidney disease

.Taking the mat is actually Judo Bio, an ambitious biotech equipped along with $one hundred million ...

AstraZeneca pays for CSPC $100M for preclinical heart disease medication

.AstraZeneca has settled CSPC Drug Group $100 million for a preclinical heart attack medicine. The b...

Zephyrm finds Hong Kong IPO to cash phase 3 tissue treatment trials

.Zephyrm Bioscience is actually gusting toward the Hong Kong stock market, declaring (PDF) for an IP...

Frazier Life Sciences gathers $630M for tiny, mid-cap biotechs

.Frazier Life Sciences has actually sourced a further $630 million for its own fund focused on tiny ...

GigaGen garners around $135M BARDA dollars to beat botulism

.Antibody enthusiast GigaGen, a subsidiary of Spanish biopharma Grifols, is increase its tech to tak...

GPCR organization Septerna files for IPO on toughness of preclinical data

.Septerna is about to figure out how a biotech without "any sort of relevant medical information" fa...